Category: Edibles
-
![First Glance with Jody Vance: Pure Extracts (PULL.C)]()
First Glance with Jody Vance: Pure Extracts (PULL.C)
In episode 69, Jody chats with Pure Extracts (PULL.C) CEO Ben Nikolaevsky to get an insight into the companies latest updates and plans. Pure Extracts operates as a cannabis and hemp extraction company in British Columbia. It is involved in the production of cannabis, cannabidiol (CBD) oil, hemp, and functional mushrooms extracts.
-
![Today’s Idea: Pure Extracts Technologies (PULL.C) is worth a closer look]()
Today’s Idea: Pure Extracts Technologies (PULL.C) is worth a closer look
Pure Extracts Technologies (PULL.C) is the Pemberton, B.C. based cannabis extractions company we showcased a few months back that’s involved in three different verticals: cannabis (and hemp) extractions, functional mushrooms and the nascent psychedelics sector. Not to belabour the point too much, but when we first started covering this company they were one to watch.…
-
![Today’s Idea: Pure Extracts Technologies (PULL.C) is worth a closer look]()
Today’s Idea: Pure Extracts Technologies (PULL.C) is worth a closer look
Pure Extracts Technologies (PULL.C) is the Pemberton, B.C. based cannabis extractions company we showcased a few months back that’s involved in three different verticals: cannabis (and hemp) extractions, functional mushrooms and the nascent psychedelics sector. Not to belabour the point too much, but when we first started covering this company they were one to watch.…
-
![The numbers: Pure Extracts (PULL.C): Q3 sees net loss but books revenue for the first time.]()
The numbers: Pure Extracts (PULL.C): Q3 sees net loss but books revenue for the first time.
Ouch! This looks like it hurt. Pure Extracts has a market cap of $37.94 Million, is down -39.84% Year to Date, but up 24.19% in the last three months. Marketwatch has a “Buy” rating for the company. In terms of technicals, I favor the upside. Why? (Link to the full write up) – Vishal Toora…
-
Harborside (HBOR.C) books 2020 revenues of $63 million – 130% of its market cap
Harborside’s full year 2020 gross revenues expanded 29% year-over-year to $63.4 million.
-
![Pure Extracts (PULL.C) to enter U.S. market through JV in Michigan]()
Pure Extracts (PULL.C) to enter U.S. market through JV in Michigan
If the LOI becomes a binding contract, Pure Extracts will contribute “a mix of equipment and cash to the venture”, which will allow the partners to rapidly scale-up to meet the rising demand for recreation cannabis concentrates and edibles throughout Michigan.
-
![As Australia opens to cannabis, Canntab’s (PILL.C) tech might just claim the box seat]()
As Australia opens to cannabis, Canntab’s (PILL.C) tech might just claim the box seat
News this week that Canntab Therapeutics (PILL.C) received an Australian patent for their hard-pressed cannabis pill tech, to match those received earlier in North America, didn’t launch the stock into space. That’s understandable, to be honest, as North American investors have taken an eye off the island continent and its slow roll to weed legalization…
-
![Harborside (HBOR.C) invests $5-million in Loudpack – a CA cultivator with a deep portfolio of branded products]()
Harborside (HBOR.C) invests $5-million in Loudpack – a CA cultivator with a deep portfolio of branded products
Loudpack is a California cannabis company with “a broad cultivation, manufacturing, processing, and distribution footprint and a strong portfolio of brands”.
-
Pure Extracts (PULL.C) looks to level up with dealers license application
At a time when many cannabis companies are enjoying bursts of investor interest, management at BC-based extractor Pure Extracts (PULL.C) must be getting frustrated as they roll out new contracts, new manufacturing lines, and advance in their pursuit of licensing that would allow them to break out into psychedelics. In essence, they’re hitting all the…
-
![Canntab Therapeutics (PILL.C) racks up revenue as CBD caplets shipped to Medipharm (LABS.T)]()
Canntab Therapeutics (PILL.C) racks up revenue as CBD caplets shipped to Medipharm (LABS.T)
Cannabis hard tablet IP holder Canntab Therapeutics (PILL.C) continues to send product to market, announcing Wednesday they’ve fulfilled 80% of their contract with Medipharm Labs (LABS.T), bringing in another half million dollars in revenue toward the $1.3 million deal announced last June. Orders under the agreement are a mix of Canntab’s proprietary instant release tablets…
